Evidence map›Paper›PMID 41422090›Full record

ArticleNature communications2025

Cryo-EM structure of TMEM164 reveals distinct phospholipid remodeling mechanisms with anti-ferroptotic potential.

Minjing Ke, Yuanyue Shan, Ziwei Zhai, Guoqiang Yao, Xinyi Guo, Xiaoxi Li, Zichao Wu, Huifeng Chen, Mengmeng Zhang, Meiyu Chen and 8 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Minjing Ke *CAS Key Laboratory of Regenerative Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.ORCID http://orcid.org/0000-0003-4728-6918
Yuanyue Shan *Laboratory of Cell Fate Control, School of Life Sciences, Westlake University, Hangzhou, China.
Ziwei Zhai *Laboratory of Cell Fate Control, School of Life Sciences, Westlake University, Hangzhou, China.
Guoqiang Yao *Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, Hong Kong, China.
Xinyi Guo *School of Life Sciences, South China Normal University, Guangzhou, China.
Xiaoxi LiLaboratory of Cell Fate Control, School of Life Sciences, Westlake University, Hangzhou, China.
Zichao WuCAS Key Laboratory of Regenerative Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Huifeng ChenCentre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, Hong Kong, China.
Mengmeng ZhangLaboratory of Cell Fate Control, School of Life Sciences, Westlake University, Hangzhou, China.
Meiyu ChenSchool of Life Sciences, South China Normal University, Guangzhou, China.
Ying LiLaboratory of Cell Fate Control, School of Life Sciences, Westlake University, Hangzhou, China.
Chengchen ZhaoLaboratory of Cell Fate Control, School of Life Sciences, Westlake University, Hangzhou, China.ORCID http://orcid.org/0000-0002-8454-6347
Bo WangLaboratory of Cell Fate Control, School of Life Sciences, Westlake University, Hangzhou, China.ORCID http://orcid.org/0000-0003-1182-952X
Micky D TortorellaCentre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, Hong Kong, China. m.tortorella@crmh-cas.org.hk.
Xiaodong ShuSchool of Biological and Chemical Engineering, Zhejiang University of Science and Technology, Hangzhou, China. shu_xiaodong@zust.edu.cn.
Mingfeng ZhangLaboratory of Cell Fate Control, School of Life Sciences, Westlake University, Hangzhou, China. zhangmingfeng@westlake.edu.cn.ORCID http://orcid.org/0000-0002-0138-3934
Junqi KuangLaboratory of Cell Fate Control, School of Life Sciences, Westlake University, Hangzhou, China. kuangjunqi@westlake.edu.cn.ORCID http://orcid.org/0009-0008-9331-6632
Duanqing PeiLaboratory of Cell Fate Control, School of Life Sciences, Westlake University, Hangzhou, China. peiduanqing@westlake.edu.cn.ORCID http://orcid.org/0000-0002-5222-014X

Funding

National Natural Science Foundation of China (National Science Foundation of China) 92068201
6 · The paper itself

Abstract

Phospholipids in cell membrane provide both regulatory and structural function of a cell. How lipid remodeling regulates cell fate remains less explored. Here we report the cryo-electron microscopy structure of TMEM164 identified by genome-wide CRISPR screen as an anti-ferroptotic factor. The overall architecture reveals a dimer of two 7 transmembrane domain monomers and a metal ion catalytic center with phospholipid substrate in a distinct polyunsaturated fatty acyl (PUFA)-C123 intermediate state. Both loss and gain of its function result in the decline of PUFA-ePE and elevation of C16/18:1-ePE, consequently confer resistance to GPX4 inhibitor RSL3 induced ferroptosis. Mutagenesis studies further validate critical residues for the catalytic center (C123) and the chelates center (E106, Y177 and H181). Through virtual screen and rational design, we identify and test candidate inhibitors for TMEM164, including activity for Montelukast S-enantiomer with 4 order of magnitude higher affinity. Our works not only demonstrates TMEM164 as a membrane lipid remodeler that controls the ferroptotic fate, but also highlights the power of integrating multi-scale platforms to unravel distinct mechanisms and functions.

Indexed as

FerroptosisMembrane ProteinsPhospholipidsCatalytic DomainCell MembraneCryoelectron MicroscopyFatty Acids, UnsaturatedHEK293 CellsHumansFatty Acids, UnsaturatedMembrane ProteinsPhospholipids

Identifiers

PMID41422090
PMCPMC12830759

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.